Acorda Therapeutics Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 4/10/2024)
| Balance Sheet | Total Assets | 117,745,000.00 | ROE | – |
| Balance Sheet | Total Equity | -157,956,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -264,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -14,248,000.00 | – | – |
| Cashflow | Operating Cash Flow | -13,984,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -203.57 | Div. Yield | – |
| Income | Net Income | -252,854,000.00 | P/E | – |
| Income | Shares Outstanding | 1,242,000.00 | P/B | – |
| Income | Total Revenue | 117,633,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system. Ampyra (dalfampridine) is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP). It also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride, a short-acting drug for the management of spasticity. Ampyra is marketed as Fampyra outside the United States by Biogen Idec International GmbH (Biogen Idec). On February 6, 2012, the Company launched tizanidine hydrochloride capsules, an authorized generic version of Zanaflex Capsules under an agreement with Watson Pharma, Inc. In December 2012, the Company acquired Neuronex, Inc.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.acorda.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more